{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:41Z","timestamp":1786118861641,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/wnf.0b013e318123ee01","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T03:12:50Z","timestamp":1211944370000},"page":"173-175","source":"Crossref","is-referenced-by-count":9,"title":["Aripiprazole and Haloperidol"],"prefix":"10.1097","volume":"31","author":[{"given":"Joseph","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Gwo","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic.","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1368-5031.2005.00498.x","article-title":"Aripiprazole in schizophrenia: consensus guidelines.","volume":"59","author":"Travis","year":"2005","journal-title":"Int J Clin Pract"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications.","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-2007-1014417","article-title":"Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression.","volume":"25","author":"Benkert","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis.","volume":"109","author":"Tamminga","year":"2002","journal-title":"J Neural Transm"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10401230600614678","article-title":"Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist.","volume":"18","author":"Burke","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","article-title":"Worsening schizoaffective disorder with aripiprazole.","volume":"161","author":"Reeves","year":"2004","journal-title":"Am J Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200805000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:10:38Z","timestamp":1786036238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200805000-00006"}},"subtitle":["Beneficial Combination Antipsychotic Therapy for a Schizophrenic Patient"],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318123ee01","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}